Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 7/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24411682 | 0.87 | ACKR3 (0.41) | KMT2APOLBLMNASMN1; SMN2ACKR3 | |
| SCHEMBL23683059 | 0.83 | KDM4E (0.53) | KMT2APOLBLMNAHRH3CYP2D6 | |
| SCHEMBL24411693 | 0.83 | ACKR3 (0.38) | KMT2APOLBLMNAHRH3ACKR3 | |
| SCHEMBL31272490 | 0.81 | HRH3 (0.40) | KMT2APOLBHRH3CYP2D6SMN1; SMN2 | |
| SCHEMBL12026414 | 0.79 | HRH3 (0.46) | KMT2AHRH3CYP2D6SMN1; SMN2KCNH2 | |
| SCHEMBL8277379 | 0.79 | POLB (0.51) | KMT2APOLBLMNASMN1; SMN2TP53 | |
| SCHEMBL19605448 | 0.79 | HDAC8 (0.48) | KMT2AHRH3CYP2D6SMN1; SMN2KCNH2 | |
| SCHEMBL20329132 | 0.78 | HRH3 (0.48) | KMT2AHRH3CYP2D6SMN1; SMN2KCNH2 | |
| SCHEMBL103478 | 0.78 | POLB (0.47) | KMT2APOLBLMNASMN1; SMN2TP53 | |
| SCHEMBL21004319 | 0.78 | POLB (0.50) | KMT2APOLBLMNASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954239-B2 | Imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof | CANWELL BIOTECH LIMITED (CN) | 2021-03-23 | — | — | US | disclosed |
| US-20200407358-A1 | IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | CANWELL BIOTECH LIMITED (HK) | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10954239-B2 | Imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof | TLR8, TLR7, TLR1 | KMT2A 475/4885POLB 2799/4885LMNA 3434/4885 |
| US-20200407358-A1 | IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | TLR8, TLR7, TLR1 | KMT2A 475/4885POLB 2799/4885LMNA 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.